The Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL) study was a real-world study that evaluated the efficacy of SGLT2i in T2DM patients, compared to other glucose-lowering drugs, across several countries [86]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.